Skip to main content
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp — Investor Relations & Filings

Ticker · SLXN ISIN · KYG1281K1141 LEI · 254900063EP9AZODNJ85 US Professional, scientific and technical activities
Filings indexed 192 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country KY Cayman Islands
Listing US SLXN

About Silexion Therapeutics Corp

https://www.moringaac.com/

Silexion Therapeutics Corp. is a clinical-stage biotechnology company that discovers and develops proprietary treatments for KRAS-driven cancers, with a primary focus on pancreatic cancer. The company pioneers RNA interference (RNAi)-based therapies and advanced delivery systems to address significant therapeutic challenges and extend patient survival. Its lead product candidate is SIL-204. Silexion collaborates with partners on formulation development and clinical manufacturing to advance its tumor-targeting technology through clinical trials.

Recent filings

Filing Released Lang Actions
8-K - Silexion Therapeutics Corp (0002022416) (Filer)
Regulatory Filings
2026-04-28 English
DEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
Proxy Solicitation & Information Statement
2026-04-09 English
8-K - Silexion Therapeutics Corp (0002022416) (Filer)
Regulatory Filings
2026-03-24 English
8-K - Silexion Therapeutics Corp (0002022416) (Filer)
Regulatory Filings
2026-03-23 English
4 - SILEXION THERAPEUTICS CORP (0002022416) (Filer)
Director's Dealing
2026-02-25 English
4 - SILEXION THERAPEUTICS CORP (0002022416) (Filer)
Director's Dealing
2026-02-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.